August 16, 2017 03:27 PM EDT
R&D

Novo's semaglu­tide hand­i­ly whips Eli Lil­ly's Trulic­i­ty in a PhI­II di­a­betes show­down

John Carroll

Editor & Founder

No­vo Nordisk had some more up­beat pipeline news to re­port Wednes­day af­ter­noon, as re­searchers rolled out new Phase III da­ta show­ing their GLP-1 drug semaglu­tide …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times